Sequential Use of Androgen Receptor Axis-targeted Agents in Chemotherapy-naive Castration-resistant Prostate Cancer: A Multicenter Retrospective Analysis With 3-Year Follow-up

Kobayashi, Takashi; Terada, Naoki; Kimura, Takahiro; Matsubara, Nobuaki; Murakami, Kimiya; Mori, Keiichiro; Fujimoto, Yasufumi; Akamatsu, Shusuke; Inoue, Takahiro; Ogawa, Osamu

doi:10.1016/j.clgc.2019.09.011

Cited by 9 publications

(7 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The PSA response rate was higher in the ENZ arm, although there were no significant differences in any survival outcomes between the arms. These results are similar to findings from previous studies [11] , [20] . Interestingly, a recent systematic review and meta-analysis revealed no significant difference in OS improvement between ENZ and ABI, but ENZ was superior to ABI in improving rPFS and TTPP for patients with metastatic CRPC [25] .…”

Section: Discussionsupporting

confidence: 93%

“…Similar results were retrospectively reported for 255 CRPC patients in Japan without chemotherapy. Longer TTPP was observed after second-line ENZ treatment following ABI than after the reverse-order sequence (median 3.67 vs 2.07 mo; HR 0.67, 95% CI 0.51–0.87; p = 0.021) [20] . However, no prospective randomized trials have investigated the priority for these agents as single agents rather than for sequential use.…”

Section: Discussionmentioning

confidence: 91%

See 1 more Smart Citation

Enzalutamide Versus Abiraterone plus Prednisolone Before Chemotherapy for Castration-resistant Prostate Cancer: A Multicenter Randomized Controlled Trial

Izumi

Shima

Mita

et al. 2022

European Urology Open Science

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 93%

Section: Discussionmentioning

confidence: 91%

Enzalutamide Versus Abiraterone plus Prednisolone Before Chemotherapy for Castration-resistant Prostate Cancer: A Multicenter Randomized Controlled Trial

Izumi

Shima

Mita

et al. 2022

European Urology Open Science

View full text Add to dashboard Cite

“…The median (95% CI) OS from the initiation of DOC was 22 (18)(19)(20)(21)(22)(23)(24)(25)(26) months. Cox proportional hazard analyses were performed for OS using the same parameters used for PFS.…”

Section: Resultsmentioning

confidence: 99%

“…These results indicate that DOC followed by CBZ might be the most appropriate treatment sequence for patients with metastatic CRPC resistant to ARAT. We previously reported that the number of life‐prolonging agents such as ARAT, DOC, CBZ or Radium‐223 was positively correlated with longer survival of CRPC patients 19 . However, as far as USA real world data, only 11% of patients received CBZ as a third line therapy for CRPC 20 .…”

Section: Discussionmentioning

confidence: 99%

The efficacy of sequential therapy with docetaxel and cabazitaxel for castration‐resistant prostate cancer: A retrospective multi‐institutional study in Japan

et al. 2022

Self Cite

View full text Add to dashboard Cite

Abbreviations & Acronyms ADT = androgen deprivation therapy ALP = alkaline phosphatase ARAT = androgen receptor axis-targeting agents CBZ = cabazitaxel CI = confidence interval CRPC = castration-resistant prostate cancer CSPC = castration-sensitive prostate cancer DOC = docetaxel GS = Gleason's score Hb = hemoglobin HR = hazard ratio IQR = interquartile range LDH = lactate dehydrogenase OS = overall survival PFS = progression-free survival PS = performance status PSA = prostate-specific antigen RDI = relative dose intensity

show abstract

“…Cabazitaxel can retain activity in patients progressing on prior docetaxel, abiraterone or enzalutamide ( 10–12 ). Despite this, many patients receive androgen-signalling-targeted inhibitors in sequence before receiving cabazitaxel therapy ( 13 , 14 ).…”

Section: Introductionmentioning

confidence: 99%

Cabazitaxel versus abiraterone or enzalutamide in metastatic castration-resistant prostate cancer: post hoc analysis of the CARD study excluding chemohormonal therapy for castrate-naive disease

Suzuki

Castellano

Bono

et al. 2021

Japanese Journal of Clinical Oncology

View full text Add to dashboard Cite

Background In the CARD study (NCT02485691), cabazitaxel significantly improved clinical outcomes versus abiraterone or enzalutamide in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel and the alternative androgen-signalling-targeted inhibitor. However, some patients received docetaxel or the prior alternative androgen-signalling-targeted inhibitor in the metastatic hormone-sensitive (mHSPC) setting. Therefore, the CARD results cannot be directly translated to a Japanese population. Methods Patients (N = 255) received cabazitaxel (25 mg/m2 IV Q3W, prednisone, G-CSF) versus abiraterone (1000 mg PO, prednisone) or enzalutamide (160 mg PO) after prior docetaxel and progression ≤12 months on the alternative androgen-signalling-targeted inhibitor. Patients who received combination therapy for mHSPC were excluded (n = 33) as docetaxel is not approved in this setting in Japan. Results A total of 222 patients (median age 70 years) were included in this subanalysis. Median number of cycles was higher for cabazitaxel versus androgen-signalling-targeted inhibitors (7 versus 4). Clinical outcomes favoured cabazitaxel over abiraterone or enzalutamide including, radiographic progression-free survival (rPFS; median 8.2 versus 3.4 months; P < 0.0001), overall survival (OS; 13.9 versus 11.8 months; P = 0.0102), PFS (4.4 versus 2.7 months; P < 0.0001), confirmed prostate-specific antigen response (37.0 versus 14.4%; P = 0.0006) and objective tumour response (38.9 versus 11.4%; P = 0.0036). For cabazitaxel versus androgen-signalling-targeted inhibitor, grade ≥ 3 adverse events occurred in 55% versus 44% of patients, with adverse events leading to death on study in 2.7% versus 5.7%. Conclusions Cabazitaxel significantly improved outcomes including rPFS and OS versus abiraterone or enzalutamide and are reflective of the Japanese patient population. Cabazitaxel should be considered the preferred treatment option over abiraterone or enzalutamide in this setting.

show abstract

Sequential Use of Androgen Receptor Axis-targeted Agents in Chemotherapy-naive Castration-resistant Prostate Cancer: A Multicenter Retrospective Analysis With 3-Year Follow-up

Cited by 9 publications

References 18 publications

Enzalutamide Versus Abiraterone plus Prednisolone Before Chemotherapy for Castration-resistant Prostate Cancer: A Multicenter Randomized Controlled Trial

Enzalutamide Versus Abiraterone plus Prednisolone Before Chemotherapy for Castration-resistant Prostate Cancer: A Multicenter Randomized Controlled Trial

The efficacy of sequential therapy with docetaxel and cabazitaxel for castration‐resistant prostate cancer: A retrospective multi‐institutional study in Japan

Cabazitaxel versus abiraterone or enzalutamide in metastatic castration-resistant prostate cancer: post hoc analysis of the CARD study excluding chemohormonal therapy for castrate-naive disease

Contact Info

Product

Resources

About